Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 North America Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 North America Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 North America Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. North America Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 North America Aflibercept Market by Country
5.2 North America Ranibizumab Market by Country
5.3 North America Others Market by Country
Chapter 6. North America Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 North America Wet Market by Country
6.2 North America Dry Market by Country
Chapter 7. North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 North America Hospital Pharmacy Market by Country
7.2 North America Retail Pharmacy Market by Country
7.3 North America Online Pharmacy Market by Country
Chapter 8. North America Age Related Macular Degeneration (AMD) Market by Country
8.1 US Age Related Macular Degeneration (AMD) Market
8.1.1 US Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 US Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 US Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 Canada Age Related Macular Degeneration (AMD) Market
8.2.1 Canada Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 Canada Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 Canada Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 Mexico Age Related Macular Degeneration (AMD) Market
8.3.1 Mexico Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 Mexico Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 Mexico Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 Rest of North America Age Related Macular Degeneration (AMD) Market
8.4.1 Rest of North America Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 Rest of North America Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 Rest of North America Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
Unique Offerings 